Trastuzumab deruxtecan
D967UC00001
Phase 3 small_molecule active
Quick answer
Trastuzumab deruxtecan for Breast Cancer; HER2-positive; Metastatic is a Phase 3 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AstraZeneca
- Indication
- Breast Cancer; HER2-positive; Metastatic
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active